Anavex Life Sciences has recently announced encouraging findings from their phase 2b/3 clinical
trial involving the investigational drug, blarcamesine (ANAVEX®2-73). This
trial, which focused on patients with early Alzheimer’s disease, demonstrated
significant reductions in pathological amyloid-ß levels and a slowing in brain
atrophy, as evidenced by MRI scans.
The trial enrolled 508 participants from 52 medical research centers across five countries.
Patients were randomized to receive either blarcamesine or a placebo for 48
weeks. Primary endpoints included the Alzheimer’s Disease Assessment
Scale-Cognitive and the Alzheimer’s Disease Cooperative Study-Activities of
Daily Living subscales. The results were statistically significant, showing a
notable difference in cognitive and functional efficacy between the treatment and placebo groups.
Researchers observed a significant anti-amyloid effect of blarcamesine, as indicated by the
increased plasma Aβ42/40 ratio. Additionally, MRI analyses revealed that
blarcamesine-treated participants exhibited markedly reduced brain volume loss
compared to the placebo group. The findings suggest that blarcamesine not only
targets amyloid-ß pathology but also addresses broader aspects of neurodegeneration.
Dr. Marwan Noel Sabbagh, a professor of neurology and chairman of the Scientific Advisory
Board, emphasized the drug’s potential. “The advantage of blarcamesine is
that it is a small oral molecule that has demonstrated clinical benefits on
both cognition and neurodegeneration,” he stated.
According to Anavex Life Sciences, the trial also noted that the most common
treatment-emergent adverse event was transient dizziness, which was generally
mild to moderate in severity. Despite this, the overall safety profile of
blarcamesine remained favorable.
Christopher U Missling, PhD, president and CEO of Anavex Life Sciences, expressed his
gratitude to all involved in the study. “We are committed to advancing
blarcamesine as a potential new treatment option for Alzheimer’s disease,” he remarked.
These promising findings from Anavex offer new hope in the ongoing battle against Alzheimer’s, bringing
attention to a novel therapeutic approach that could potentially improve the
lives of millions affected by this devastating disease.
Read this article for additional information.
Follow their page on https://twitter.com/AnavexLifeSci